Beat Steiner ā Head of Drug Discovery Biology and Vice President at Actelion
Executive Bio
Mr. Beat Steiner served as the Head of Drug Discovery - Biology and Vice President at Actelion Ltd., since July 2009. Mr. Steiner serves as the Head of Drug Discovery Biology and Vice President at Actelion Pharmaceuticals U.S., Inc. He served as a Member of the Management Board at Actelion Ltd. In 2003, he joined the drug discovery unit at Actelion Pharmaceuticals Ltd. He has 20 years of experience in drug discovery at F. Hoffmann-La Roche. During his almost 20 years at Roche Basel, he initiated the research project on platelet integrin receptor antagonists, which led to the discovery and clinical development of lamifiban and sibrafiban. He was leading a drug discovery group in the field of thrombosis and atherosclerosis resulting in the selection of several additional compounds for clinical development. He served as Deputy Head of Pharmacology and Preclinical Development at Actelion from 2003 to June 2009. Mr. Steiner studied biochemistry/chemistry and obtained his PhD degree at the University of Berne. During his postdoctoral education, he received further training in molecular biology and pharmacology from the University of California in San Francisco.
Executive Team Culture Ratings from Actelion Employees
TOP
15%
Actelion's Executive Team scores in the Top 15%
of similar sized companies on Comparably
of similar sized companies on Comparably
Not Enough Ratings To Show Who Ranks Executive Team the Highest
Anonymously rate my experience at ActelionNot Enough Ratings To Show Who Ranks Executive Team the Lowest
Anonymously rate my experience at ActelionActelion's Executive Team at a Glance
Based on 3 ratings, Actelion's employees are very satisfied with their Executive Team and give them an āA-ā or 77/100.
Actelion's Executive Team ranks in the Top 15% of other companies on Comparably that also have 1,001-5,000 Employees.
×